Salarius Pharmaceuticals Inc(SLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLRX Salarius Pharmaceuticals Inc

Pre-Market Trading 01-10 05:52:00 EST

1.63

-0.08

-4.68%

High1.71	Low1.62	Vol30.06K
Open1.71	D1 Closing1.71	Amplitude5.26%
Mkt Cap2.35M	Tradable Cap2.17M	Total Shares1.44M
T/O49.76K	T/O Rate2.26%	Tradable Shares1.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SLRX","market":"US","secType":"STK","nameCN":"Salarius Pharmaceuticals Inc","latestPrice":1.63,"timestamp":1736370000000,"preClose":1.71,"halted":0,"volume":30056,"delay":0,"floatShares":1329188,"shares":1441157,"eps":-6.893912,"marketStatus":"Pre-Market Trading","change":-0.08,"latestTime":"01-10 05:52:00 EST","open":1.71,"high":1.71,"low":1.62,"amount":49755.528940000004,"amplitude":0.052632,"askPrice":2.01,"askSize":100,"bidPrice":1.5,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-6.893912,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736519400000},"marketStatusCode":1,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":1.63,"postHourTrading":{"tag":"盘后","latestPrice":1.61,"preClose":1.63,"latestTime":"19:59 EST","volume":228,"amount":368.11,"timestamp":1736384344391},"volumeRatio":0.1744375725417548},"requestUrl":"/m/hq/s/SLRX/tweets","defaultTab":"tweets","newsList":[{"id":"2491232553","title":"BRIEF-Salarius Pharmaceuticals Enters Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2491232553","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491232553?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:22","pubTimestamp":1734088972,"startTime":"0","endTime":"0","summary":"BRIEF-Salarius Pharmaceuticals Enters Securities Purchase AgreementDec 13  - Salarius Pharmaceuticals Inc SLRX.O:SALARIUS PHARMACEUTICALS INC - ENTERS SECURITIES PURCHASE AGREEMENTSALARIUS PHARMACEUTICALS INC - AGREEMENT ALLOWS SALE OF UP TO $10 MILLION IN SHARESFurther company coverage: SLRX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2491323809","title":"Salarius Pharmaceuticals Inc - Enters Securities Purchase Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2491323809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491323809?lang=en_us&edition=fundamental","pubTime":"2024-12-13 19:02","pubTimestamp":1734087758,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241213:nFWN3NE0KA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRX","BK4139"],"gpt_icon":0},{"id":"2483371843","title":"Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371843","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483371843?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:04","pubTimestamp":1731679484,"startTime":"0","endTime":"0","summary":"* Salarius Pharmaceuticals Inc    reported a quarterly adjusted loss of 76 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Salarius Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRX"],"gpt_icon":0},{"id":"2483368016","title":"Salarius: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2483368016","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483368016?lang=en_us&edition=fundamental","pubTime":"2024-11-15 08:25","pubTimestamp":1731630328,"startTime":"0","endTime":"0","summary":"HOUSTON  — HOUSTON  — Salarius Pharmaceuticals, Inc.  on Thursday reported a loss of $972,000 in its third quarter.The Houston-based company said it had a loss of 76 cents per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/salarius-q3-earnings-snapshot-002528075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLRX"],"gpt_icon":0},{"id":"2458542437","title":"Salarius: Q2 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2458542437","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458542437?lang=en_us&edition=fundamental","pubTime":"2024-08-10 05:21","pubTimestamp":1723238496,"startTime":"0","endTime":"0","summary":"HOUSTON  — HOUSTON  — Salarius Pharmaceuticals, Inc.  on Friday reported a loss of $1.4 million in its second quarter.On a per-share basis, the Houston-based company said it had a loss of $2.37.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/salarius-q2-earnings-snapshot-212136692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLRX"],"gpt_icon":1},{"id":"2454087743","title":"Dow Jumps 200 Points; Honeywell Trims Profit Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2454087743","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2454087743?lang=en_us&edition=fundamental","pubTime":"2024-07-25 22:39","pubTimestamp":1721918389,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/07/39961101/dow-jumps-200-points-honeywell-trims-profit-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EZFL","BK4139","TWOU","LU0787776722.HKD","PBM","BK4204","SLRX","PSQ","POAI","HON","QID","MNQmain","BK4585","NQmain","IE0034235188.USD","BK4082","QLD","LU0683600562.USD","TQQQ","BK4196","KDLY","BK4198","BK4588","BK4534",".IXIC","IE00B1BXHZ80.USD","BK4122","BK4550","BK4144","SQQQ","PCOM","BK4206"],"gpt_icon":1},{"id":"2452284377","title":"BUZZ-Salarius Pharma falls on ending early-stage bone cancer study","url":"https://stock-news.laohu8.com/highlight/detail?id=2452284377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452284377?lang=en_us&edition=fundamental","pubTime":"2024-07-20 05:46","pubTimestamp":1721425583,"startTime":"0","endTime":"0","summary":"** Shares of drug developer Salarius Pharmaceuticals  fall 4.4% to $1.75 after the bell     ** Co to close its ongoing early-stage trial testing its experimental drug seclidemstat in patients with a type of bone cancer   ** Co says it is ending the study in an effort to conserve cash while its board of directors continues its exploration of potential strategic alternatives   ** The US FDA placed a partial clinical hold on another cancer study testing seclidemstat in patients with a type of blood cancer on July 11    ** Up to last close, stock down 64.8% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BUZZ","SLRX"],"gpt_icon":1},{"id":"2452871281","title":"BRIEF-Salarius Pharmaceuticals Says Now Determined To Close Ongoing Phase 1/2 Clinical Trial Evaluating Seclidemstat For Ewing Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2452871281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452871281?lang=en_us&edition=fundamental","pubTime":"2024-07-20 05:20","pubTimestamp":1721424006,"startTime":"0","endTime":"0","summary":"July 19  - Salarius Pharmaceuticals Inc :   * SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA   * SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING CLINICAL TRIAL IN AN EFFORT TO CONSERVE CASH   * SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF POTENTIAL STRATEGIC ALTERNATIVES   * SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT  IN COMBINATION WITH AZACITIDINESource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLRX"],"gpt_icon":0},{"id":"2452890682","title":"SALARIUS PHARMACEUTICALS INC: NOW DETERMINED TO CLOSE ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING SECLIDEMSTAT FOR EWING SARCOMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2452890682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452890682?lang=en_us&edition=fundamental","pubTime":"2024-07-20 05:15","pubTimestamp":1721423714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240719:nFWN3JB1AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4581","LU0820561818.USD","BK4097","LU2125909247.SGD","LU0943347566.SGD","LU1917777945.USD","LU1923622614.USD","BK4585","LU2458330243.SGD","BK4550","LU1153585028.USD","LU1923622291.USD","LU1803068979.SGD","LU0109392836.USD","LU1551013342.USD","LU2063271972.USD","LU2023250504.SGD","LU2286300806.USD","INC","SLRX","NOW","LU0109391861.USD","FOR","LU1923623000.USD","LU0820561909.HKD","LU2264538146.SGD","LU2433249047.HKD","LU1064131342.USD","BK4024","LU1988902786.USD","BK4534","LU0316494557.USD","LU1989764664.SGD","LU2023250843.SGD","IE00BMPRXN33.USD","LU2125909593.SGD","LU2458330169.SGD","LU2106854487.HKD","LU0672654240.SGD","LU1323610961.USD","IE00BMPRXR70.SGD","LU0689472784.USD","LU0011850046.USD","BK4528","LU0354030438.USD","LU1951198990.SGD","LU0708995401.HKD","LU0320765059.SGD","LU1951200564.SGD","BK4566"],"gpt_icon":0},{"id":"2452628906","title":"SALARIUS PHARMACEUTICALS INC: CONTINUES ITS EXPLORATION OF POTENTIAL STRATEGIC ALTERNATIVES","url":"https://stock-news.laohu8.com/highlight/detail?id=2452628906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452628906?lang=en_us&edition=fundamental","pubTime":"2024-07-20 05:15","pubTimestamp":1721423714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240719:nFWN3JB1AK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INC","SLRX"],"gpt_icon":0},{"id":"2452289061","title":"SALARIUS PHARMACEUTICALS INC - TERMINATING THE ONGOING CLINICAL TRIAL IN AN EFFORT TO CONSERVE CASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2452289061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452289061?lang=en_us&edition=fundamental","pubTime":"2024-07-20 05:15","pubTimestamp":1721423714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240719:nFWN3JB1AK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRX","BK4139","BK4211","INC","CASH"],"gpt_icon":0},{"id":"2452281813","title":"SALARIUS PHARMACEUTICALS: TO CONTINUE SUPPORT FOR MDACC'S SPONSORED CLINICAL TRIAL EVALUATING SECLIDEMSTAT (SP-2577) IN COMBINATION WITH AZACITIDINE","url":"https://stock-news.laohu8.com/highlight/detail?id=2452281813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2452281813?lang=en_us&edition=fundamental","pubTime":"2024-07-20 05:15","pubTimestamp":1721423714,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240719:nFWN3JB1AK:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRX","SP","BK4139","BK4024","BK4120","FOR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salariuspharma.com","stockEarnings":[{"period":"1week","weight":-0.1141},{"period":"1month","weight":0.0795},{"period":"3month","weight":0.1014},{"period":"6month","weight":-0.1768},{"period":"1year","weight":-0.6943},{"period":"ytd","weight":-0.1141}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.3,"avgChangeRate":-0.016488},{"month":2,"riseRate":0.4,"avgChangeRate":-0.000908},{"month":3,"riseRate":0.5,"avgChangeRate":0.031094},{"month":4,"riseRate":0.2,"avgChangeRate":-0.075189},{"month":5,"riseRate":0.5,"avgChangeRate":-0.013003},{"month":6,"riseRate":0.5,"avgChangeRate":-0.069204},{"month":7,"riseRate":0.3,"avgChangeRate":-0.116732},{"month":8,"riseRate":0.3,"avgChangeRate":-0.087267},{"month":9,"riseRate":0.1,"avgChangeRate":-0.102733},{"month":10,"riseRate":0.3,"avgChangeRate":-0.147148},{"month":11,"riseRate":0.4,"avgChangeRate":0.007387},{"month":12,"riseRate":0.3,"avgChangeRate":-0.04821}],"exchange":"NASDAQ","name":"Salarius Pharmaceuticals Inc","nameEN":"Salarius Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Salarius Pharmaceuticals Inc(SLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Salarius Pharmaceuticals Inc(SLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Salarius Pharmaceuticals Inc,SLRX,Salarius Pharmaceuticals Inc股票,Salarius Pharmaceuticals Inc股票老虎,Salarius Pharmaceuticals Inc股票老虎国际,Salarius Pharmaceuticals Inc行情,Salarius Pharmaceuticals Inc股票行情,Salarius Pharmaceuticals Inc股价,Salarius Pharmaceuticals Inc股市,Salarius Pharmaceuticals Inc股票价格,Salarius Pharmaceuticals Inc股票交易,Salarius Pharmaceuticals Inc股票购买,Salarius Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Salarius Pharmaceuticals Inc(SLRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Salarius Pharmaceuticals Inc(SLRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction